Through multidimensional research and collaboration, overcoming existing challenges, SGLT-2 inhibitors hold the potential to provide significant clinical benefits for more non-diabetic CKD patients, advancing the treatment of CKD and related chronic diseases, and improving patients’ quality of life (165). Here, SLC5A2 is linked to chronic kidney disease.